My research interests are in translational cardiovascular epidemiology with a focus on the study of novel signaling pathways and mechanisms in human heart failure, cardiac remodeling, and cancer therapy cardiotoxicity. Current areas of research include:
1) Neuregulin Signaling:
We are interested in defining the relevance of circulating neuregulin as it relates to human heart failure and cardiac remodeling. I am the principal investigator of a longitudinal study determining the association between circulating neuregulin levels and cardiac remodeling and clinical outcomes in the Penn Heart Failure Study
and the Chronic Renal Insufficiency Cohort
2) Mechanistic Biomarker Studies in Cancer Therapy Cardiotoxicity:
We are interested in defining novel circulating biomarkers and genetic variations predictive of cancer therapy cardiotoxicity. Our objective is to gain mechanistic and translational insight into the pathophysiology of this disease. We have ongoing studies in specific pathways and biomarkers of interest, as well as proteomics discovery across various cardiotoxic regimens.
3) Myocardial Mechanics in Cancer Therapy Cardiotoxicity and Heart Failure:
We are interested in gaining insight into alterations in myocardial mechanics and sensitive measures of cardiac function, as defined by echocardiography, in patients exposed to cardiotoxic chemotherapy regimens as well as patients with chronic heart failure.
French B, Wang L, Ky B, Fang JC, Sweitzer NK, Cappola TP. : Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. Journal of Cardiac Failure 22(4): 256-62, April 2016.
Armenian SH, Xu L, Ky B, Sun C, Farol L, Pal S, Douglas PS, Bhatia S, Chao C. : Late Occurring Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community Based Retrospective Study. Journal of Clinical Oncology 34(10): 1120-30, April 2016.
Narayan HK, Khan AM, French B, Plappert T, Hyman D, Bajulaiye A, DeMichele A, Domchek S, Clark A, Fox K, Matro J, Bradbury A, Carver JR, Ky B.: Echocardiography-Derived Measures of Myocardial Mechanics Predict Cardiotoxicity with Breast Cancer Therapy. Journal of the American College of Cardiology Imaging. Journal of the American College of Cardiology Imaging April 2016 Notes: Epub ahead of print.
Brown JC, Troxel AB, Ky B, Damjanov N, Zemel BS, Rickels MR, Rhim AD, Rustgi AK, Courneya KS, Schmitz KH: A randomized phase II dose-response exercise trial among Colon Cancer Survivors: Purpose, Study Design, methods, and recruitment results. Contemp Clinical Trials 47: 366-375, March 2016.
Wang GJ, Shaw PA, Townsend RR, Anderson AH, Xie D, Wang X, Nessel LC, Mohler III ER, Sozio SM, Jaar BG, Chen J, Wright J, Taliercio JJ, Ojo A, Ricardo AC, Lustigiva E, Fairman RM, Feldman HI, Ky B: Sex Differences in the Incidence of Peripheral Artery Disease (PAD) in the Chronic Renal Insufficiency Cohort (CRIC). Circulation: Cardiovascular Quality and Outcomes 1: S86-93, January 2016.
Porteous MK, Ky B, Fitzpatrick JN, Plappert T, Diamond JM, Shah RJ, Brown M, Christie JD, Kawut SM: Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction After Lung Transplantation American Journal of Respiratory and Critical Care Medicine January 2016 Notes: Epub ahead of print.
St. John Sutton, M. Cerkvenik J, Borlaug BA, Daubert C, Gold MR, Ghio S, Linde C, Ky B: The Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results from the Resynchronization reverses Remodeling in Systolic left ventricular dysfunction (REVERSE). Journal of the American Heart Association 4(9), September 2015.
Putt ME, Hahn Shalkey V, Sawaya H, French B, Sebag I, Plana JC, Januzzi JL, Tan TC, Cohen V, Banchs J, Carver J, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M, Ky B. : Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clinical Chemistry 61(9): 1164-72, September 2015.
Tchou J, Lam L, Li YR, Edwards C, Ky B, Zhang H: Monitoring Serum HER2 Levels in Breast Cancer Patients. Springer Plus Breast Cancer Collection 4(237), May 2015 Notes: doi: 10.1186/s40064-015-1015-6.
Haas, N Manola J, Ky B, Flaherty K, Uzzo RG, Kane CJ, Jewett M, Wood CG, Atkin MB, Dutcher JJ, DiPaolo RS: Effects of Sorafenib and Sunitinib on Cardiac Function in a Population without Overt Metastases: Cardiac Sub-study of a Phase III Trial of Sunitinib or Sorafenib or Placebo in Patients with High Risk Resected Renal Cell Carcinoma (E2805). Clinical Cancer Research May 2015.
back to top
Last updated: 05/05/2016
The Trustees of the University of Pennsylvania